We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals

24 hedge funds and large institutions have $30.6M invested in Corbus Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 2

232% more capital invested

Capital invested by funds: $9.21M → $30.6M (+$21.4M)

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

9% more funds holding

Funds holding: 2224 (+2)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
24
Holders Change
+2
Holders Change %
+9.09%
% of All Funds
0.64%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
8
Increased
10
Reduced
2
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
PA
1
Perceptive Advisors
New York
$9.57M +$5.1M +65,000 +156%
KCM
2
Knoll Capital Management
Florida
$7.67M
CAM
3
Cormorant Asset Management
Massachusetts
$5.98M +$5.23M +66,667 New
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.96M +$443K +5,644 +35%
DCM
5
DAFNA Capital Management
California
$1.2M +$1.05M +13,333 New
GTC
6
Ghost Tree Capital
New York
$897K +$784K +10,000 New
RJFSA
7
Raymond James Financial Services Advisors
Florida
$792K -$26.3K -336 -4%
BIT
8
BlackRock Institutional Trust
California
$566K
Renaissance Technologies
9
Renaissance Technologies
New York
$439K +$236K +3,010 +160%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$429K +$137K +1,745 +57%
Creative Planning
11
Creative Planning
Kansas
$369K +$315K +4,016 +3,899%
BFA
12
BlackRock Fund Advisors
California
$251K +$85.2K +1,087 +63%
YP
13
Yellowstone Partners
Idaho
$130K
Northern Trust
14
Northern Trust
Illinois
$96K +$17.6K +224 +26%
Morgan Stanley
15
Morgan Stanley
New York
$80K +$55.7K +710 +401%
EAM
16
Evanson Asset Management
California
$60K +$26.2K +334 +100%
Nomura Holdings
17
Nomura Holdings
Japan
$36K +$33.2K +423 New
Citadel Advisors
18
Citadel Advisors
Florida
$32K +$27.9K +356 New
BA
19
BlackRock Advisors
Delaware
$18K
BIM
20
BlackRock Investment Management
Delaware
$17K +$7.13K +91 +88%
UBS Group
21
UBS Group
Switzerland
$7K -$1.65K -21 -22%
Walleye Trading
22
Walleye Trading
New York
$5K +$4.16K +53 New
AG
23
Advisor Group
Arizona
$5K +$5.25K +67 New
JP Morgan Chase
24
JP Morgan Chase
New York
$3K +$2.59K +33 New
RJA
25
Raymond James & Associates
Florida
-$153K -2,815 Closed

CRBP Hedge Fund Activity: Q2 2016 in Review

24 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2016, worth a combined $30.6M — up 232% from $9.21M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new CRBP positions and 6 closed out — a net gain of 2 holders — while 10 added to existing stakes and 2 trimmed.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $5.23M. The largest seller was Raymond James & Associates, exiting entirely with an estimated $153K sold.

  • 24 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2016, up from 22 in Q1 2016.
  • Funds reported $30.6M of Corbus Pharmaceuticals stock for Q2 2016, up 232% quarter-over-quarter.
  • 8 funds opened new Corbus Pharmaceuticals positions in Q2 2016 and 6 closed out, a net change of +2 holders.
  • The largest Corbus Pharmaceuticals buyer in Q2 2016 was Cormorant Asset Management, an estimated $5.23M added.
  • The largest Corbus Pharmaceuticals seller in Q2 2016 was Raymond James & Associates, an estimated $153K sold.

Based on aggregated 13F filings for Q2 2016.